Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Oct;12(10):2233-2247.
doi: 10.1007/s13555-022-00799-7. Epub 2022 Sep 17.

Comorbidities in Androgenetic Alopecia: A Comprehensive Review

Affiliations
Review

Comorbidities in Androgenetic Alopecia: A Comprehensive Review

Shuang Chen et al. Dermatol Ther (Heidelb). 2022 Oct.

Abstract

Androgenetic alopecia is the most common form of hair loss, affecting 85% of men and 40% of women. Androgenetic alopecia is a disease caused by multiple factors, such as genetics, hormones, and systemic diseases; however, the exact cause remains undetermined. Recent studies have found that it is associated with a high incidence of endocrine diseases and other comorbidities. It may not only be a skin disease but also an early signal of underlying systemic diseases. Effective management requires timely diagnosis and treatment initiation. However, in current clinical practice, androgenetic alopecia is still not fully understood or treated. Recognizing the true physical, social, and emotional burden of androgenic alopecia, as well as its associated comorbidities, is the first step in improving the prognosis of affected patients. This review aimed to gather the known pathological factors and provide a reference for clinical physicians to understand androgenetic alopecia and its comorbidities in depth, thereby enabling early recognition of the underlying systemic diseases and providing timely treatment.

Keywords: Androgenetic alopecia; Comorbidities; Systemic diseases.

PubMed Disclaimer

References

    1. Cash TF. The psychosocial consequences of androgenetic alopecia: a review of the research literature. Br J Dermatol. 1999;141(3):398–405. doi: 10.1046/j.1365-2133.1999.03030.x. - DOI - PubMed
    1. Rajabi F, Drake LA, Senna MM, Rezaei N. Alopecia areata: a review of disease pathogenesis. Br J Dermatol. 2018;179:1033–1048. doi: 10.1111/bjd.16808. - DOI - PubMed
    1. Elsaie LT, Elshahid AR, Hasan HM, et al. Cross sectional quality of life assessment in patients with androgenetic alopecia. Dermatol Ther. 2020;33(4):e13799. doi: 10.1111/dth.13799. - DOI - PubMed
    1. Sorbellini E, Pinto D, Marzani B, Rinaldi F. Drug treatment for androgenetic alopecia: first Italian questionnaire survey on what dermatologists think about finasteride. Dermatol Ther. 2018;8:259–267. doi: 10.1007/s13555-018-0233-6. - DOI - PMC - PubMed
    1. Girijala RL, Riahi RR, Cohen PR. Platelet-rich plasma for androgenic alopecia treatment: a comprehensive review. Dermatol Online J. 2018;24(7):13030. doi: 10.5070/D3247040910. - DOI - PubMed

LinkOut - more resources